Prof. Dollar retweeted
Replying to @RxRegA
What was far more troubling was a sitting CBER director speaking anonymously to reporters to publicly discredit an investigational Huntington’s therapy under his own agency’s review.
Calling AMT-130 a “failed product,” disputing prior regulatory commitments, and dismissing the concerns of families facing an irreversible, fatal disease deserved public scrutiny.
@adamfeuerstein did his job. Federal regulators wielding extraordinary power over patients’ futures should not be shielded from public scrutiny by anonymity. The public deserves transparency and accountability, not regulatory interference behind closed doors.
Prof. Dollar retweeted
🚨🗣️Ivan Jovanović on Netherlands’ incredible 7-0 humiliation of Greece:
“I have been involved in football for many years, but honestly, I have never seen anything like this in my life.
The way the Netherlands played was shocking. We couldn’t even get close to the ball. Every time we tried to press, they had already found another passing option. It felt like we were always two steps behind.
Xavi genuinely surprised me. His tactical ideas were something else. The positioning, the movement, the way they controlled every area of the pitch. It was unbelievable.
At some point, I stopped trying to understand how we could get the ball back and started watching how they were moving it.
What impressed me most was how comfortable every player looked. Nobody was rushing, nobody was panicking. They knew exactly where their teammates would be before the ball even arrived.
Even when we tried to change our pressing structure, they found solutions immediately. It was like they had already anticipated everything we wanted to do.
I’ve seen great teams before, but this was different.
For once in my life, I watched the Netherlands play football like prime Barcelona. The confidence, the possession, the intelligence and the constant movement. Everything was there.
I actually want to sit down with Xavi and ask him more about this style. I want to understand how he gets his players to execute these movements so perfectly. There is clearly something special happening in that dressing room.
I also have to give credit to the players. You can have the best tactical instructions in the world, but executing them at that level requires extraordinary intelligence and understanding.
Because tonight, we weren’t just beaten by a better team. We were completely outplayed in every department.
We were given a footballing lesson. And Xavi was the professor.”
$QURE's gene therapy for Hemophilia B is cheaper than lifelong factor IX prophylaxis in Sweden.
Per patient, over a lifetime. Fewer bleeds, more quality-adjusted life years, millions saved, 90% predicted to keep FIX activity above 5% for 60 years.
pubmed.ncbi.nlm.nih.gov/4282…
1-2 What if $QURE's next innovation isn't a new therapy, but a smarter business model?
One-time gene therapy, with recurring payments linked to sustained efficacy and long-term patient outcomes.
Small payments per patient could add up to substantial recurring revenue over years.
1
7
1,788
2-2 And here's what @uniQure_NV should have learned: don't let #AMT130 become another headline about the world's most expensive therapy.
$QURE's Glybera and Hemgenix showed how eye-watering one-time price tags can dominate the conversation.
One treatment, long-term value. 🧬
1
1
664
Prof. Dollar retweeted
1/ $QURE Guggenheim transcript from today's presentation.
As always, this is a fast draft transcript created from iPhone recording turned into raw transcript run through ChatGPT. THERE ARE MOST LIKELY TYPOS. I have not read it yet.
#CapitalRotation Big Pharma faces a massive patent cliff. Hundreds of billions in revenues are at risk. Hunt for biotech acquisitions is on. Watch for value inflection points.👇
$QURE: #AMT130, potential first disease-modifying treatment for Huntington's. FDA decision: May 1, '27
20
932
Prof. Dollar retweeted
$QURE: Useful commercial detail in Guggenheim’s Nov. 2 “Top Pick” note:
-Physician checks identify ~24 US sites with intraoperative MRI and ClearPoint capability. Guggenheim envisages ~25 treatments/month during the first six months after launch, rising toward ~50/month in the second six.
-The ~6,000 addressable symptomatic patients cited already account for striatal-volume requirements and some access barriers.
-The note references a $2.5–4.0m pricing range, although an actual launch price remains unconfirmed.
Guggenheim also views the planned AdCom as potentially constructive, expecting clinicians and patients to support AMT-130’s benefit–risk profile.
Prof. Dollar retweeted
If you watch one video today, it should be this.
@FDA_KyleD please rapidly speed up the review process for @uniQure_NV $QURE AMT130 for families like Heather's. Remove the unethical, unnecessary burden of the confirmatory trial by using currently treated patients along with following the first 100-150 commercially treated patients for confirmation.
Time Matters
@laurencurehd
@Christina4HD
@JRenz0418
@rachelreising96
@geneveritas
@SenRonJohnson
@SenRickScott
@RepAuchincloss
@houmanhemmati
@adamfeuerstein
@armstrongdrew
@l_e_whyte
@temple_west
@ScottGottliebMD
@BeckyQuick
@davidfaber
@AllysiaFinley
@bradloncar
@docrodwong
@LuckyPenguin10
@POTUS
@SenateAging
@SenBillCassidy
@SenRandPaul
@WhiteHouse
@FDACBER
@FDA_KyleD
@DrOzCMS
@HHSGov
#Duchenne
#PrimaryImmunodeficiency
#RareDisease
#HuntingtonsDisease
#FDA #PatientAdvocacy
#PatientVoice
#TimeMatters
#RareDiseaseResearch
#RareDiseaseFramework
@RickSantorum
@FoxNews
@bariweiss
@60Minutes
@CNBC
@WSJopinion
@WSJ
@statnews
Prof. Dollar retweeted
Replying to @FDA
CNPV for AMT-130. Every single day untreated for Huntingtons patients brings harm they can never reverse. The 4 month difference between AA and CNPV evaluation could be the difference for hundreds between being able to recieve lifesaving treatment or being too far gone to help.
Prof. Dollar retweeted
Sorry to add to the bad news today…
Novartis $NVS cites cases of previously unknown tumors possibly tied to its SMA gene therapy statnews.com/2026/11/05/nova… via @Jasonmmast @pharmalot
Prof. Dollar retweeted
$RARE is an example of recent gene therapy approval from August 2026 without the need for a real placebo-controlled trial and is instead using data from commercially treated patients. @FDA_KyleD please change the alignment with @uniQure_NV $QURE AMT130 to a similar design.
It will be unethical to follow HD patients for 3 years who never receive treatment until after the 3 years.
@laurencurehd
@Christina4HD
@JRenz0418
@rachelreising96
@geneveritas
@SenRonJohnson
@SenRickScott
@RepAuchincloss
@houmanhemmati
@adamfeuerstein
@armstrongdrew
@l_e_whyte
@temple_west
@ScottGottliebMD
@BeckyQuick
@davidfaber
@AllysiaFinley
@bradloncar
@docrodwong
@LuckyPenguin10
@POTUS
@SenateAging
@SenBillCassidy
@SenRandPaul
@WhiteHouse
@SusieWiles
@FDACBER
@FDA_KyleD
@DrOzCMS
@HHSGov
#Duchenne
#PrimaryImmunodeficiency
#RareDisease
#HuntingtonsDisease
#FDA #PatientAdvocacy
#PatientVoice
#TimeMatters
#RareDiseaseResearch
#RareDiseaseFramework
Prof. Dollar retweeted
$QURE We are now in the commercial launch chapter of the company. Time to start modelling what amt-130 is worth as a franchise.
1. Already talking to payers, there is ‘strong interest’. Already engaged NICE, NHS in England.





























